Wound Care Biologics Market Research Report – Forecast to 2023

Report / Search Code: MRFR/HC/5101-HCRR  Publish Date: January, 2019

Price

<table>
<thead>
<tr>
<th></th>
<th>1-user PDF</th>
<th>Enterprise PDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$4450.0</td>
<td>$6250.0</td>
</tr>
</tbody>
</table>

Description:

Global Wound Care Biologics Research Report: Information by Product Type (Biological Skin Substitutes, Topical Agents), by Wound Type (Surgical and Traumatic Wounds, Diabetic Foot Ulcer, Pressure Ulcers), End User (Hospitals, Clinics)—Forecast till 2023

Market Scenario

The global wound care biologics market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 1.20 billion in 2017 and is projected to grow at a CAGR of 9.9% over the forecast period. Wound care biologics products create an active healing environment which allows the body to heal wound naturally. The wound care biologics are mainly used to the management of diabetic ulcers, venous ulcers, arterial ulcers, and pressure ulcers.

The factors such as the increasing prevalence of chronic diseases and burn injuries, and increasing healthcare expenditure are expected to propel the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in 2015, about 2.8 million people were hospitalized due to injuries. However, the high cost of treatment, lack of awareness, and poor education and training hamper the market growth over the forecast period.

Segmentation

The global wound care biologics market has been segmented into product type, wound type, and end user.

Based on product type, has been segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is expected to account for the largest share and fastest growing segment of the market in 2017.

The market, by wound type, has been segmented into ulcers, surgical & traumatic wounds, and burns. The ulcers segment has been further segmented into diabetic foot ulcers, pressure ulcers, venous leg ulcer, and others.

The market, by end user, has been segmented into hospitals, ambulatory surgical centers, and clinics.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wound care biologics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European wound care biologics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The wound care biologics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wound care biologics market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players

Integra LifeSciences Corporation (US), Smith & Nephew (UK), Wright Medical (US), Mölnlycke Health Care AB (Sweden), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Marine Polymer Technologies, Inc. (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), and Organogenesis (US) are some of the key players in the global wound care biologics market.

Regional Market Summary

Global Wound Care Biologics Market Share (%), by Region, 2017

Source: Centers for Disease Control and Prevention (CDC), National Diabetes Statistics, and Annual Reports,

Geographically, the Americas is anticipated to dominate the global wound care biologics market owing to a well-developed healthcare sector, growing occurrences of chronic wounds, rising prevalence of diabetes and rising geriatric population. According to the National Diabetes Statistics Report 2017, about 30.3 million suffer from diabetes in Americans.

Europe is expected to hold the second largest position in the global wound care biologics market. The market growth in this region is attributed to the increasing prevalence of diabetes and developed healthcare infrastructure.

The wound care biologics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the huge patient population of chronic diseases such as diabetes in countries such as India and China.

The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Global Wound Care Biologics Market, by Product Type

- Skin Substitute
- Human Donor Tissue
- Acellular animal-derived
- Biosynthetic

- Topical Agents

Global Wound Care Biologics Market, by Wound Type

- Ulcers
- Diabetic foot ulcers
- Venous ulcers
- Pressure ulcers
- Other ulcers
- Surgical and Traumatic Wounds
- Burns

Global Wound Care Biologics Market, by End User
- Hospitals
- Clinics
- Other End Users

Global Wound Care Biologics Market, by Region

- Americas
  - North America
    - US
    - Canada
    - South America
  - South America
- Asia-Pacific
  - Japan
  - China
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific
- The Middle East & Africa
  - Middle East
  - Africa

Intended Audience
8.1 Introduction

8.2 Hospitals
Market Estimates & Forecast, by Region, 2018–2023

8.3 Clinics
Market Estimates & Forecast, by Region, 2018–2023

8.4 Other End Users
Market Estimates & Forecast, by Region, 2018–2023

Chapter 9. Global Wound Care Biologics Market, by Region

9.1 Introduction

9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America

9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Integra LifeSciences Corporation
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Smith & Nephew
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Wright Medical
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Mölnlycke Health Care AB
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 MiMedx Group
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Vericel Corporation
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Anika Therapeutics
11.7.1 Overview
11.7.2 Product Overview
Table 29 Asia-Pacific: Wound Care Biologics Market, by Product Type, 2018–2023 (USD Million)
Table 30 Asia-Pacific: Wound Care Biologics Market, by Wound Type, 2018–2023 (USD Million)
Table 31 Asia-Pacific: Wound Care Biologics Market, by End User, 2018–2023 (USD Million)
Table 32 Middle East & Africa: Wound Care Biologics Market, by Product Type, 2018–2023 (USD Million)
Table 33 Middle East & Africa: Wound Care Biologics Market, by Wound Type, 2018–2023
Table 34 Middle East & Africa: Wound Care Biologics Market, by End User, 2018–2023 (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Wound Care Biologics Market
Figure 3 Segmentation Market Dynamics for Global Wound Care Biologics Market
Figure 4 Global Wound Care Biologics Market Share, by Product Type, 2017
Figure 5 Global Wound Care Biologics Market Share, by Wound Type, 2017
Figure 6 Global Wound Care Biologics Market Share, by End User, 2017
Figure 7 Global Wound Care Biologics Market Share, by Region, 2017
Figure 8 North America: Wound Care Biologics Market Share, by Country, 2017
Figure 9 Europe: Wound Care Biologics Market Share, by Country, 2017
Figure 10 Asia-Pacific: Wound Care Biologics Market Share, by Country, 2017
Figure 11 Middle East & Africa: Wound Care Biologics Market Share, by Country, 2017
Figure 12 Global Wound Care Biologics Market: Company Share Analysis, 2017 (%)
Figure 13 Integra LifeSciences Corporation: Key Financials
Figure 14 Integra LifeSciences Corporation: Segmental Revenue
Figure 15 Integra LifeSciences Corporation: Geographical Revenue
Figure 16 Smith & Nephew: Key Financials
Figure 17 Smith & Nephew: Segmental Revenue
Figure 18 Smith & Nephew: Geographical Revenue
Figure 19 Wright Medical: Key Financials
Figure 20 Wright Medical: Segmental Revenue
Figure 21 Wright Medical: Geographical Revenue
Figure 22 Mölnlycke Health Care AB: Key Financials
Figure 23 Mölnlycke Health Care AB: Segmental Revenue
Figure 24 Mölnlycke Health Care AB: Geographical Revenue
Figure 25 MiMedx Group: Key Financials
Figure 26 MiMedx Group: Segmental Revenue
Figure 27 MiMedx Group: Geographical Revenue
Figure 28 Vericel Corporation: Key Financials
Figure 29 Vericel Corporation: Segmental Revenue
Figure 30 Vericel Corporation: Geographical Revenue
Figure 31 Anika Therapeutics: Key Financials
Figure 32 Anika Therapeutics: Segmental Revenue
Figure 33 Anika Therapeutics: Geographical Revenue
Figure 34 Osiris Therapeutics: Key Financials
Figure 35 Osiris Therapeutics: Segmental Revenue
Figure 36 Osiris Therapeutics: Geographical Revenue
Figure 37 Organogenesis: Key Financials
Figure 38 Organogenesis: Segmental Revenue
Figure 39 Organogenesis: Geographical Revenue
Figure 40 Solsys Medical: Key Financials
Figure 41 Solsys Medical: Segmental Revenue
Figure 42 Solsys Medical: Geographical Revenue
Figure 43 ACell: Key Financials
Figure 44 ACell: Segmental Revenue
Figure 45 ACell: Geographical Revenue
Figure 46 Kerecis: Key Financials
Figure 47 Kerecis: Segmental Revenue
Figure 48 Kerecis: Geographical Revenue